

IN THE CLAIMS:

Please amend claim 1 as follows:

B1
SUB
D1

1. A pharmaceutical composition, comprising a ligand which binds specifically to glial-derived or meningioma-derived tumor cells and a pharmaceutically acceptable carrier, wherein said ligand is selected from the group consisting of antibody which recognizes an antigen that is a glioma or meningioma specific chloride channel and a chlorotoxin-like compound.

Please cancel claims 2 and 3.

In claim 4, line 1 please replace "3" with --1--.

REMARKS

Applicant submits the following remarks. The specification has been corrected per Examiner's suggestion. Reconsideration of the pending claims as amended in view of the remarks *infra* is respectfully requested. Claims 1-4 are pending currently. No new matter has been added.